https://www.marketscreener.com/quote/stock/GALECTO-INC-114282637/news/GALLANT-1-GB1211-Galectin-3-Gal-3-inhibitor-plus-atezolizumab-atz-for-first-line-treatment-in-p-45125042/?utm_source=telegram&utm_medium=social&utm_campaign=share